US5948384A
(en)
*
|
1990-09-14 |
1999-09-07 |
Syngenix Limited |
Particulate agents
|
GB9020075D0
(en)
|
1990-09-14 |
1990-10-24 |
Filler Aaron G |
Contrast agents for magnetic resonance imaging of axonal transport
|
US5543390A
(en)
|
1990-11-01 |
1996-08-06 |
State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University |
Covalent microparticle-drug conjugates for biological targeting
|
US5827819A
(en)
*
|
1990-11-01 |
1998-10-27 |
Oregon Health Sciences University |
Covalent polar lipid conjugates with neurologically active compounds for targeting
|
US6919067B2
(en)
|
1991-09-13 |
2005-07-19 |
Syngenix Limited |
Compositions comprising a tissue glue and therapeutic agents
|
CA2141216A1
(en)
*
|
1992-07-27 |
1994-02-03 |
Michael J. Micklus |
Targeting of liposomes to the blood-brain barrier
|
DE4303646A1
(en)
*
|
1993-02-09 |
1994-08-11 |
Basf Ag |
The use of thrombin inhibitors to combat neurodegenerative diseases
|
AU7564194A
(en)
*
|
1993-09-10 |
1995-03-27 |
University Of Medicine And Dentistry Of New Jersey |
Blood-brain barrier transporters of neurological agents
|
DE69529054T2
(en)
*
|
1994-02-28 |
2003-08-21 |
Nanopharm Ag |
SYSTEM FOR TARGETED ACTIVE SUBSTANCE, METHOD FOR THE PRODUCTION AND USE THEREOF
|
ES2312177T3
(en)
|
1996-05-22 |
2009-02-16 |
Viventia Biotech Inc. |
FRAGMENTS OF UNION TO ANTIGENS THAT SPECIFICALLY DETECT CANCER CELLS, NUCLEOTIDES THAT CODIFY FRAGMENTS AND THE USE OF THE SAME FOR THE PROFILAXIS AND CANCER DETECTION.
|
JP2001508648A
(en)
|
1996-11-06 |
2001-07-03 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Tumor necrosis factor receptor releasing enzyme, composition containing the enzyme, and method of using the same
|
US7115722B1
(en)
|
1997-05-22 |
2006-10-03 |
Viventia Biotech, Inc. |
Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
|
GB9721901D0
(en)
|
1997-10-16 |
1997-12-17 |
Univ Manchester |
Particles
|
WO2002009700A1
(en)
|
2000-07-28 |
2002-02-07 |
Cancer Research Technology Limited |
Cancer treatment by combination therapy
|
US8251986B2
(en)
|
2000-08-17 |
2012-08-28 |
Angiodynamics, Inc. |
Method of destroying tissue cells by eletroporation
|
US7795232B1
(en)
|
2000-08-25 |
2010-09-14 |
Genta Incorporated |
Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
|
PA8536201A1
(en)
|
2000-12-29 |
2002-08-29 |
Kenneth S Warren Inst Inc |
PROTECTION AND IMPROVEMENT OF CELLS, FABRICS AND ORGANS RESPONDING TO Erythropoietin
|
US7629309B2
(en)
|
2002-05-29 |
2009-12-08 |
Zystor Therapeutics, Inc. |
Targeted therapeutic proteins
|
US7560424B2
(en)
|
2001-04-30 |
2009-07-14 |
Zystor Therapeutics, Inc. |
Targeted therapeutic proteins
|
IL158623A0
(en)
|
2001-04-30 |
2004-05-12 |
Symbiontics Inc |
Subcellular targeting of therapeutic proteins
|
US6994706B2
(en)
|
2001-08-13 |
2006-02-07 |
Minnesota Medical Physics, Llc |
Apparatus and method for treatment of benign prostatic hyperplasia
|
GB0121285D0
(en)
|
2001-09-03 |
2001-10-24 |
Cancer Res Ventures Ltd |
Anti-cancer combinations
|
WO2003032727A1
(en)
*
|
2001-10-16 |
2003-04-24 |
Symbiontics Inc. |
Methods and compositions for targeting underglycosylated proteins across the blood brain barrier
|
US20030072761A1
(en)
|
2001-10-16 |
2003-04-17 |
Lebowitz Jonathan |
Methods and compositions for targeting proteins across the blood brain barrier
|
GB2386836B
(en)
|
2002-03-22 |
2006-07-26 |
Cancer Res Ventures Ltd |
Anti-cancer combinations
|
KR101086533B1
(en)
|
2002-05-24 |
2011-11-23 |
쉐링 코포레이션 |
Neutralizing human anti-IGFR antibody, a method for producing it and a composition comprising it
|
GB2394658A
(en)
|
2002-11-01 |
2004-05-05 |
Cancer Rec Tech Ltd |
Oral anti-cancer composition
|
US7834147B2
(en)
*
|
2003-04-28 |
2010-11-16 |
Childrens Hospital Medical Center |
Saposin C-DOPS: a novel anti-tumor agent
|
PT2274978E
(en)
|
2003-09-12 |
2015-07-09 |
Ipsen Biopharmaceuticals Inc |
Methods for treatment of insulin-like growth factor-i(igf-i) deficiency
|
ATE514783T1
(en)
|
2003-11-12 |
2011-07-15 |
Schering Corp |
PLASMID SYSTEM FOR EXPRESSING MULTIPLE GENES
|
TW200526684A
(en)
|
2003-11-21 |
2005-08-16 |
Schering Corp |
Anti-IGFR1 antibody therapeutic combinations
|
US20050244400A1
(en)
|
2004-02-10 |
2005-11-03 |
Zystor Therapeutics, Inc. |
Acid alpha-glucosidase and fragments thereof
|
JP2008521907A
(en)
|
2004-12-03 |
2008-06-26 |
シェーリング コーポレイション |
Biomarkers for preselecting patients for anti-IGF1R treatment
|
WO2006085149A2
(en)
|
2004-12-22 |
2006-08-17 |
Neurochem (International) Limited |
Methods and compositions for treating amyloid-related diseases
|
US9988427B2
(en)
|
2005-05-13 |
2018-06-05 |
Charite Universitaetsmedizen-Berlin |
Erythropoietin variants
|
WO2006126208A2
(en)
*
|
2005-05-26 |
2006-11-30 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
|
PT2371855E
(en)
|
2005-08-05 |
2015-11-03 |
Araim Pharmaceuticals Inc |
Tissue protective peptides and uses thereof
|
DK2089417T3
(en)
|
2006-10-12 |
2015-03-23 |
Bhi Ltd Partnership |
Methods, Compounds, Compositions and Vehicles for Delivery of 3-Amion-1-Propanesulfonic Acid
|
US8895303B2
(en)
|
2006-11-13 |
2014-11-25 |
Charite-Universitatsmedizin Berlin |
Method of cell culture and method of treatment comprising a vEPO protein variant
|
EP2155769B1
(en)
|
2007-05-04 |
2012-06-27 |
Katholieke Universiteit Leuven KU Leuven Research & Development |
Tissue degeneration protection
|
WO2009094172A2
(en)
|
2008-01-22 |
2009-07-30 |
Araim Pharmaceuticals, Inc. |
Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
|
CA2721568A1
(en)
*
|
2008-04-17 |
2009-10-22 |
Banyan Biomarkers, Inc. |
An antibody bound synthetic vesicle containing active agent molecules
|
US9867652B2
(en)
|
2008-04-29 |
2018-01-16 |
Virginia Tech Intellectual Properties, Inc. |
Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds
|
US8992517B2
(en)
|
2008-04-29 |
2015-03-31 |
Virginia Tech Intellectual Properties Inc. |
Irreversible electroporation to treat aberrant cell masses
|
US10702326B2
(en)
|
2011-07-15 |
2020-07-07 |
Virginia Tech Intellectual Properties, Inc. |
Device and method for electroporation based treatment of stenosis of a tubular body part
|
US10238447B2
(en)
|
2008-04-29 |
2019-03-26 |
Virginia Tech Intellectual Properties, Inc. |
System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress
|
US9283051B2
(en)
|
2008-04-29 |
2016-03-15 |
Virginia Tech Intellectual Properties, Inc. |
System and method for estimating a treatment volume for administering electrical-energy based therapies
|
US10272178B2
(en)
|
2008-04-29 |
2019-04-30 |
Virginia Tech Intellectual Properties Inc. |
Methods for blood-brain barrier disruption using electrical energy
|
US9598691B2
(en)
|
2008-04-29 |
2017-03-21 |
Virginia Tech Intellectual Properties, Inc. |
Irreversible electroporation to create tissue scaffolds
|
US10245098B2
(en)
|
2008-04-29 |
2019-04-02 |
Virginia Tech Intellectual Properties, Inc. |
Acute blood-brain barrier disruption using electrical energy based therapy
|
US10117707B2
(en)
|
2008-04-29 |
2018-11-06 |
Virginia Tech Intellectual Properties, Inc. |
System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies
|
US11272979B2
(en)
|
2008-04-29 |
2022-03-15 |
Virginia Tech Intellectual Properties, Inc. |
System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies
|
US11254926B2
(en)
|
2008-04-29 |
2022-02-22 |
Virginia Tech Intellectual Properties, Inc. |
Devices and methods for high frequency electroporation
|
US9198733B2
(en)
|
2008-04-29 |
2015-12-01 |
Virginia Tech Intellectual Properties, Inc. |
Treatment planning for electroporation-based therapies
|
HUE034850T2
(en)
|
2008-05-07 |
2018-03-28 |
Biomarin Pharm Inc |
Lysosomal targeting peptides and uses thereof
|
EP2342356A4
(en)
|
2008-09-29 |
2012-11-21 |
Univ Ben Gurion |
Amyloid beta-peptides and methods of use thereof
|
WO2010108503A1
(en)
|
2009-03-24 |
2010-09-30 |
Life & Brain Gmbh |
Promotion of neuronal integration in neural stem cell grafts
|
US11382681B2
(en)
|
2009-04-09 |
2022-07-12 |
Virginia Tech Intellectual Properties, Inc. |
Device and methods for delivery of high frequency electrical pulses for non-thermal ablation
|
US11638603B2
(en)
|
2009-04-09 |
2023-05-02 |
Virginia Tech Intellectual Properties, Inc. |
Selective modulation of intracellular effects of cells using pulsed electric fields
|
WO2010138919A2
(en)
|
2009-05-28 |
2010-12-02 |
Angiodynamics, Inc. |
System and method for synchronizing energy delivery to the cardiac rhythm
|
US9895189B2
(en)
|
2009-06-19 |
2018-02-20 |
Angiodynamics, Inc. |
Methods of sterilization and treating infection using irreversible electroporation
|
EP2327725A1
(en)
|
2009-11-26 |
2011-06-01 |
InflaRx GmbH |
Anti-C5a binding moieties with high blocking activity
|
EP2509953B1
(en)
|
2009-12-11 |
2016-03-30 |
Genecode AS |
Methods of facilitating neural cell survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators
|
US9700368B2
(en)
|
2010-10-13 |
2017-07-11 |
Angiodynamics, Inc. |
System and method for electrically ablating tissue of a patient
|
EP2637652A2
(en)
|
2010-11-10 |
2013-09-18 |
Katholieke Universiteit Leuven |
Osteoclast activity
|
WO2012088149A2
(en)
|
2010-12-20 |
2012-06-28 |
Virginia Tech Intellectual Properties, Inc. |
High-frequency electroporation for cancer therapy
|
JP6038122B2
(en)
|
2011-04-21 |
2016-12-07 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Functional magnetic nanoparticles and their use in image processing of amyloid deposits and neurofibrillary tangles
|
MX2014007664A
(en)
|
2011-12-22 |
2015-05-11 |
Nuvo Res Gmbh |
Liposomal chlorite or chlorate compositions.
|
WO2014140934A2
(en)
|
2013-03-11 |
2014-09-18 |
Life Science Nutrition As |
Natural lipids containing non-oxidizable fatty acids
|
CA3052449C
(en)
|
2013-03-11 |
2021-10-19 |
Jan Remmereit |
Lipid compositions comprising 5, 11, 14-eicosatrienoic acid and conjugated linoleic acids
|
EP3088518A4
(en)
|
2013-12-25 |
2017-09-20 |
JCR Pharmaceuticals Co., Ltd. |
Novel anti-transferrin receptor antibody that passes through blood-brain barrier
|
WO2015175570A1
(en)
|
2014-05-12 |
2015-11-19 |
Virginia Tech Intellectual Properties, Inc. |
Selective modulation of intracellular effects of cells using pulsed electric fields
|
US10694972B2
(en)
|
2014-12-15 |
2020-06-30 |
Virginia Tech Intellectual Properties, Inc. |
Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment
|
CA3033694C
(en)
|
2016-09-15 |
2023-06-27 |
Universitat Stuttgart |
Antigen binding protein against her3
|
WO2018087720A1
(en)
|
2016-11-14 |
2018-05-17 |
Novartis Ag |
Compositions, methods, and therapeutic uses related to fusogenic protein minion
|
US10905492B2
(en)
|
2016-11-17 |
2021-02-02 |
Angiodynamics, Inc. |
Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode
|
US10376595B2
(en)
|
2017-04-03 |
2019-08-13 |
Inflarx Gmbh |
Treatment of inflammatory diseases with inhibitors of C5a activity
|
EP3411400B1
(en)
|
2017-04-03 |
2021-09-22 |
InflaRx GmbH |
Treatment of inflammatory diseases with inhibitors of c5a activity
|
CN110997693A
(en)
|
2017-06-07 |
2020-04-10 |
阿德克斯公司 |
Tau aggregation inhibitors
|
CN111201241A
(en)
|
2017-06-23 |
2020-05-26 |
因弗拉克斯有限责任公司 |
Treatment of inflammatory diseases with inhibitors of C5a activity
|
EP3668886A2
(en)
|
2017-08-18 |
2020-06-24 |
Adrx, Inc. |
Tau aggregation peptide inhibitors
|
US11607537B2
(en)
|
2017-12-05 |
2023-03-21 |
Virginia Tech Intellectual Properties, Inc. |
Method for treating neurological disorders, including tumors, with electroporation
|
US11311329B2
(en)
|
2018-03-13 |
2022-04-26 |
Virginia Tech Intellectual Properties, Inc. |
Treatment planning for immunotherapy based treatments using non-thermal ablation techniques
|
US11925405B2
(en)
|
2018-03-13 |
2024-03-12 |
Virginia Tech Intellectual Properties, Inc. |
Treatment planning system for immunotherapy enhancement via non-thermal ablation
|
CN113056286A
(en)
|
2018-09-10 |
2021-06-29 |
冷泉港实验室 |
Methods for treating pancreatitis
|
KR20210137157A
(en)
|
2019-03-11 |
2021-11-17 |
인플라알엑스 게엠베하 |
Fused piperidinyl bicyclic compounds and related compounds as receptor modulators of C5a
|
US11950835B2
(en)
|
2019-06-28 |
2024-04-09 |
Virginia Tech Intellectual Properties, Inc. |
Cycled pulsing to mitigate thermal damage for multi-electrode irreversible electroporation therapy
|
US20230158060A1
(en)
|
2020-03-27 |
2023-05-25 |
Inflarx Gmbh |
Inhibitors of C5a for the Treatment of Corona Virus Infection
|